Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious technique, conolidine modulates alternate molecular targets. A Science Innovations study identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://tonyg932qhb4.wikidirective.com/user